Aging Clinical and Experimental Research

, Volume 17, Issue 2, pp 157–163 | Cite as

Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate

  • Jun Iwamoto
  • Tsuyoshi Takeda
  • Yoshihiro Sato
  • Mitsuyoshi Uzawa
Original Articles

Abstract

Background and aims: Exercise may enhance the effect of alendronate on bone mineral density (BMD) and reduce chronic back pain in elderly women with osteoporosis. The aim of this study was to determine whether whole-body vibration exercise would enhance the effect of alendronate on lumbar BMD and bone turnover, and reduce chronic back pain in post-menopausal women with osteoporosis. Methods: Fifty post-menopausal women with osteoporosis, 55–88 years of age, were randomly divided into two groups of 25 patients each: one taking alendronate (5 mg daily, ALN) and one taking alendronate plus exercise (ALN+EX). Exercise consisted of whole-body vibration using a Galileo machine (Novotec, Pforzheim, Germany), at an intensity of 20 Hz, frequency once a week, and duration of exercise 4 minutes. The study lasted 12 months. Lumbar BMD was measured by dual energy X-ray absorptiometry (Hologic QDR 1500W). Urinary cross-linked N-terminal telopeptides of type I collagen (NTX) and serum alkaline phos-phatase (ALP) levels were measured by enzyme-linked immunosorbent assay and standard laboratory techniques, respectively. Chronic back pain was evaluated by face scale score at baseline and every 6 months. Results: There were no significant differences in baseline characteristics, including age, body mass index, years since menopause, lumbar BMD, urinary NTX and serum ALP levels, or face scale score between the two groups. The increase in lumbar BMD and the reduction in urinary NTX and serum ALP levels were similar in the ALN and ALN+EX groups. However, the reduction in chronic back pain was greater in the ALN+EX group than in the ALN group. Conclusions: The results of this study suggest that whole-body vibration exercise using a Galileo machine appears to be useful in reducing chronic back pain, probably by relaxing the back muscles in post-menopausal osteoporotic women treated with alendronate.

Keywords

Alendronate bone mineral density (BMD) elderly women osteoporosis whole-body vibration exercise 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Masud T, Giannini S. Preventing osteoporotic fractures with bisphosphonates: a review of the efficacy and tolerability. Aging Clin Exp Res 2003; 15: 89–98.PubMedGoogle Scholar
  2. 2.
    Shiraki M, Kushida K, Fukunaga M, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int 1999; 10: 183–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Kushida K, Shiraki M, Nakamura T. et al. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res 2002; 63: 606–20.Google Scholar
  4. 4.
    Miyakoshi N, Itoi E, Kobayashi M, Kodama H. Impact of postural deformities and spinal mobility on quality of life in post-menopausal osteoporosis. Osteoporos Int 2003; 14: 1007–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Iwamoto J, Takeda T, Ichimura S, Uzawa M. Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with symptomatic vertebral fractures. Keio J Med 2003; 52: 230–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Pappagallo M, Breuer B, Schneider A, Sperber K. Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records. J Pain Symptom Manage 2003; 26: 678–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Nevitt MC, Thompson DE, Black DM, et al. Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med 2000; 160: 77–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Bosco C, Cardinale M, Tsarpela O. Influence of vibration on mechanical power and electromyogram activity in human arm flexor muscles. Eur J Appl Physiol Occup Physiol 1999: 79: 306–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Russo CR, Lauretani F, Bandinelli S, et al. High-frequency vibration training increases muscle power in postmenopausal women. Arch Phys Med Rehabil 2003; 84: 1854–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Kerchan-Schindl K, Grampp S, Henk C, et al. Whole-body vibration exercise leads to alterations in muscle blood volume. Clin Physiol 2001: 3: 377–82.CrossRefGoogle Scholar
  11. 11.
    Torvinen S, Kannus P, Siebanen H. Effect of a vibration exposure on muscular performance and body balance. Randomized crossover study. Clin Physiol Funct Imaging 2002: 22: 145–52.CrossRefGoogle Scholar
  12. 12.
    Rittweger J, Just K, Kautzsch K, Reeg P, Felsenberg D. Treatment of chronic lower back pain with lumbar extension and whole-body vibration exercise: a randomized controlled trial. Spine 2002; 27: 1829–34.PubMedCrossRefGoogle Scholar
  13. 13.
    Orimo H, Sugioka Y, Fukunaga M, et al. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998; 16: 139–50.CrossRefGoogle Scholar
  14. 14.
    Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001; 19: 331–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Lorish CD, Maisiak R. The face scale: a brief, nonverbal method for assessing patient mood. Arthritis Rheum 1986; 29: 906–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Agarwala S, Sule A, Pai BU, Joshi VR. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 2002; 41: 346–7.CrossRefGoogle Scholar
  17. 17.
    Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 1999; 18: 266–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 1994; 74: 2949–55.Google Scholar
  19. 19.
    Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001; 14: 529–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Hortobagyi GN, Terhiault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785–91.PubMedCrossRefGoogle Scholar
  21. 21.
    Siris E, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res 1998; 13: 1032–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Nishikaku F, Nakayama T, Nakatsuka M. Analgesic property of bisphosphonate. etidronate in animal models. Jpn Pharmacol Ther 1998; 26: 457–63 (in Japanese).Google Scholar
  23. 23.
    Tanaka T, Nakayama T, Katsumata T. Etidronate: therapeutic agent for osteoporosis possessing analgesic effect. Bio Clinica 2001; 16: 57–61 (in Japanese).CrossRefGoogle Scholar
  24. 24.
    Iwamoto J, Takeda T, Ichimura S. Transient relief of metastatic cancer bone pain by oral administration of etidronate. J Bone Miner Metab 2002; 20: 228–34.PubMedCrossRefGoogle Scholar
  25. 25.
    Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 1999; 26: 2318–23.PubMedGoogle Scholar
  26. 26.
    Torvinen S, Kannus P, Sievanen H, et al. Effect of 8-month vertical body vibration on bone, muscle performance, and bone balance: a randomized controlled study. J Bone Miner Res 2003; 18: 876–84.PubMedCrossRefGoogle Scholar
  27. 27.
    Rubin C, Xu G, Judex S. The anabolic activity of bone tissue, suppressed by disuse, is normalized by brief exposure to extremely low-magnitude mechanical stimuli. FASEB J 2003; 15: 2225–9.CrossRefGoogle Scholar
  28. 28.
    Rubin C, Turner S, Brain S, Mallinckrodt C, McLeod K. Low mechanical signals strengthen long bones. Nature 2001; 412: 603–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Rubin C, Turner S, Muller R, et al. Quantity and quality of trabecular bone in the femur are enhanced by a strongly anabolic, noninvasive mechanical intervention. J Bone Miner Res 2002; 17: 349–57.PubMedCrossRefGoogle Scholar
  30. 30.
    Rubin C, Turner S, Mallinckrodt C, Jerome C, McLeod K, Bain S. Mechanical strain, induced noninvasively in the high-frequency domain, is anabolic to cancellous bone, but not cortical bone. Bone 2002; 30: 445–52.PubMedCrossRefGoogle Scholar
  31. 31.
    Cardinale M, Pope MH. The effects of whole body vibration on humans: dangerous or advantageous? Acta Physiol Hung 2003; 90: 195–206.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Internal Publishing Switzerland 2005

Authors and Affiliations

  • Jun Iwamoto
    • 1
  • Tsuyoshi Takeda
    • 1
  • Yoshihiro Sato
    • 2
  • Mitsuyoshi Uzawa
    • 3
  1. 1.Department of Sports MedicineKeio University School of MedicineTokyoJapan
  2. 2.Department of NeurologyMitate HospitalFukuokaJapan
  3. 3.Department of Orthopedic SurgeryKeiyu Orthopedic HospitalTatebayashi, GunmaJapan

Personalised recommendations